company background image
PJ2N

Liminal BioSciences DB:PJ2N Stock Report

Last Price

€3.21

Market Cap

€98.1m

7D

-3.2%

1Y

-84.9%

Updated

30 Jun, 2021

Data

Company Financials +
PJ2N fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health0/6
Dividends0/6

PJ2N Stock Overview

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom.

Liminal BioSciences Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Liminal BioSciences
Historical stock prices
Current Share Price€3.21
52 Week High€0
52 Week Low€0
Beta1.41
1 Month Change-6.14%
3 Month Change-9.07%
1 Year Change-84.86%
3 Year Change-99.03%
5 Year Change-99.83%
Change since IPOn/a

Recent News & Updates

Shareholder Returns

PJ2NDE BiotechsDE Market
7D-3.2%0.1%0.3%
1Y-84.9%-0.6%-20.0%

Return vs Industry: PJ2N underperformed the German Biotechs industry which returned -14.8% over the past year.

Return vs Market: PJ2N underperformed the German Market which returned 26.8% over the past year.

Price Volatility

Is PJ2N's price volatile compared to industry and market?
PJ2N volatility
PJ2N Average Weekly Movement14.1%
Biotechs Industry Average Movement8.6%
Market Average Movement5.7%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.8%

Stable Share Price: PJ2N is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PJ2N's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1994251Bruce Pritchardhttps://www.liminalbiosciences.com

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment’s lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases.

Liminal BioSciences Fundamentals Summary

How do Liminal BioSciences's earnings and revenue compare to its market cap?
PJ2N fundamental statistics
Market CapCA$144.06m
Earnings (TTM)-CA$114.28m
Revenue (TTM)CA$3.33m

37.0x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PJ2N income statement (TTM)
RevenueCA$3.33m
Cost of RevenueCA$0
Gross Profit-CA$48.39m
Other ExpensesCA$65.90m
Earnings-CA$114.28m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-4.38
Gross Margin-1,455.31%
Net Profit Margin-3,437.11%
Debt/Equity Ratio-819.0%

How did PJ2N perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PJ2N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PJ2N?

Other financial metrics that can be useful for relative valuation.

PJ2N key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue55.7x
Enterprise Value/EBITDA-2.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does PJ2N's Ratio compare to its peers?

Insufficient data to calculate this valuation analysis check
PJ2N Ratio vs Peers
The above table shows the ratio for PJ2N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyEstimated GrowthMarket Cap
Peer Averagen/a
PJ2N Liminal BioSciences
n/a14.9%€98.1m


Price to Earnings Ratio vs Industry

How does PJ2N's PE Ratio compare vs other companies in the European Biotechs Industry?


Price to Book Ratio vs Fair Ratio

What is PJ2N's Ratio compared to its Fair Ratio? This is the expected Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PJ2N Ratio vs Fair Ratio.
Fair Ratio
Current Ratio
Fair Ration/a


Share Price vs Fair Value

What is the Fair Price of PJ2N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PJ2N's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PJ2N's fair value to establish if it is undervalued.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?


Discover undervalued companies

Future Growth

How is Liminal BioSciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PJ2N is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PJ2N is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PJ2N's revenue (6.9% per year) is forecast to grow faster than the German market (4.7% per year).

High Growth Revenue: PJ2N's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PJ2N's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Liminal BioSciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-16.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PJ2N is currently unprofitable.

Growing Profit Margin: PJ2N is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PJ2N is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.

Accelerating Growth: Unable to compare PJ2N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PJ2N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.6%).


Return on Equity

High ROE: PJ2N's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Liminal BioSciences's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PJ2N has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PJ2N has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate PJ2N's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: PJ2N's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PJ2N has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PJ2N has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Liminal BioSciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PJ2N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PJ2N's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PJ2N's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PJ2N's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PJ2N has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Bruce Pritchard (47 yo)

0.58yr

Tenure

CA$1,841,985

Compensation

Mr. Bruce Pritchard, BA, CA, FioD, served as Chief Operating Officer of Small Molecule Therapeutics at Liminal BioSciences Inc. until November 2020. Mr. Pritchard served as Chief Operating Officer of Inter...


CEO Compensation Analysis

Compensation vs Market: Bruce's total compensation ($USD1.49M) is above average for companies of similar size in the German market ($USD417.90K).

Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PJ2N's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PJ2N's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.


Top Shareholders

Company Information

Liminal BioSciences Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Liminal BioSciences Inc.
  • Ticker: PJ2N
  • Exchange: DB
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €98.066m
  • Shares outstanding: 29.94m
  • Website: https://www.liminalbiosciences.com

Number of Employees


Location

  • Liminal BioSciences Inc.
  • 440 Boulevard Armand-Frappier
  • Suite 300
  • Laval
  • Quebec
  • H7V 4B4
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/30 00:00
End of Day Share Price2021/06/30 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.